Pleco Therapeutics’ mission is to demonstrate the market value and therapeutic potential of our proprietary Plecoid™ products through an initial focus on treatments for orphan cancers. Thereafter we can expand our scalable product platform for the treatment of other cancers as well as neurodegenerative disorders where aberrant metal patterns have been shown to play a role.

Our current pre-clinical development programs focus on the development of treatments for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.


Pleco Therapeutics is led by an experienced management team, with a track record in pharma and biotech, guided by our supportive Board of Directors. Our advisors include the inventor of our foundational patent; an expert in material science and metal analysis, including in cancer; and a cancer expert specializing in the interaction of metals and key proteins in cancer.

Ivo Timmermans
Chief Executive Officer
Rudi Jansen
Chief Business Officer
Dan Gelvan
Chief Research & Development Officer
Gerben de Rijk
Chief Legal Officer
Michael Stalhamer President Pleco Therapeutics USA, Inc.
Dr Henno Welgemoed Chief Medical Officer
Julie Powell Corporate Development Director
Tamara Kokaz Programme Director
Arjan Toor Chief Financial Officer
Brenda Reynolds Non-Executive Director
Gerard van Leijenhorst
Non-Executive Director
Callum Meikle Non-Executive Director

If you are interested in investing in Pleco Therapeutics please contact us